Neutral
●
Business Wire
●
3 months ago
CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary H1 2026 % Change Q2 2026 % Change $m Actual CER1 $m Actual CER - Product Sales 28,896 8 5 14,510 5 4 - Alliance Revenue 1,699 31 29 874 34 33 Product Revenue 30,595 9 6 15,384 6 5 Collaboration Revenue 77 (6) (9) - n/m n/m Total Revenue 30,672 9 6 15,384 6 5 Reported EPS ($) 3.60 4 3 1.61 2 (2) Core2 EPS ($) 5.21 12 1...